It’s the season for companies leaving their offices and taking their messages on the road to conferences to explain the challenges they are helping their customers surmount.
Accordingly, New York-based Anavex Life Sciences Corp. (NASDAQ: AVXL) announced Tuesday that CEO Christopher Missling will present a company update and participate in a panel at the 2020 BIO CEO & Investor Conference. The panel discussion is set for next Tuesday afternoon, February 11, at New York’s Marriott Marquis.
Anavex Life has dedicated itself to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer.
Its shares galloped 22 cents, or 6.7%, midday Tuesday to $3.50, on volume of 816,000 shares.